Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 5Endocrine 5Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Hepatoblastoma 5Sarcoma 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Rhabdoid Tumor 3Neuroectodermal Tumors, Primitive, Peripheral 3Medulloblastoma 3Central Nervous System Neoplasms 3Wilms Tumor 2Retinoblastoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Optic Nerve Glioma 2Liver Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Familial ependymoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Astrocytoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 4lanreotide 4Sunitinib 4Temozolomide 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Capecitabine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Quality of Life 2FAPI-46 2veliparib 1tivozanib 1tislelizumab 1telotristat ethyl 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1gallium Ga 68 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Etoposide × Gastrointestinal × Clear all
NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
37 enrolled 25 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡